Advances in Biomedical Frontier Technologies and Disease Diagnosis

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 1348

Special Issue Editor


E-Mail Website
Guest Editor
1. School of Medicine, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece
2. Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
Interests: nanomedicine; biomaterials; gene therapy; drug delivery

Special Issue Information

Dear Colleagues,

Biomedical research is experiencing a transformative shift driven by the integration of advanced technologies that improve disease diagnosis, treatment, and patient care. This Special Issue focuses on the latest innovations in biomedical frontier technologies, including nanomedicine, biomaterials, gene therapy, drug delivery, bacteriotherapy, and bioinformatics. Our goal is to highlight emerging approaches that enhance diagnostic precision, therapeutic efficacy, and personalized medicine.

Nanomedicine and biomaterials are revolutionizing the development of targeted therapies by enabling precise drug delivery and tissue regeneration. Gene therapy offers groundbreaking potential for treating hereditary and acquired diseases, while drug delivery systems are evolving to optimize treatment specificity and minimize side effects. The role of bacteriotherapy in modulating the microbiome and targeting pathological conditions represents another promising frontier in biomedical research.

This Special Issue invites original research articles and reviews covering a broad spectrum of topics, including novel nanobiotechnology applications, advances in bioinformatics-driven diagnostics, and innovative therapeutic strategies. Contributions exploring the intersection of engineering, medicine, and computational biology are particularly welcome.

By gathering cutting-edge research, this Special Issue aims to provide valuable insights into the future of biomedical science, supporting the development of novel diagnostic tools and therapeutic paradigms.

We look forward to your contributions to this exciting and rapidly evolving field.

Dr. Alexey Yaremenko
Guest Editor

Nadezhda Pechnikova
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine 
  • biomaterials 
  • gene therapy 
  • drug delivery 
  • bacteriotherapy 
  • nanobiotechnology 
  • hereditary diseases 
  • bioinformatics 
  • personalized medicine 
  • smart biomaterials

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

52 pages, 3943 KB  
Review
Applications of Modern Cell Therapies: The Latest Data in Ophthalmology
by Ioannis Iliadis, Nadezhda A. Pechnikova, Malamati Poimenidou, Diamantis D. Almaliotis, Ioannis Tsinopoulos, Tamara V. Yaremenko and Alexey V. Yaremenko
Life 2025, 15(10), 1610; https://doi.org/10.3390/life15101610 - 16 Oct 2025
Viewed by 1092
Abstract
Cell-based therapeutics are redefining interventions for vision loss by enabling tissue replacement, regeneration, and neuroprotection. This review surveys contemporary cellular strategies in ophthalmology through the lenses of therapeutic effectiveness, translational readiness, and governance. We profile principal sources—embryonic and induced pluripotent stem cells, mesenchymal [...] Read more.
Cell-based therapeutics are redefining interventions for vision loss by enabling tissue replacement, regeneration, and neuroprotection. This review surveys contemporary cellular strategies in ophthalmology through the lenses of therapeutic effectiveness, translational readiness, and governance. We profile principal sources—embryonic and induced pluripotent stem cells, mesenchymal stromal cells, retinal pigment epithelium, retinal progenitor and limbal stem cells—and enabling platforms including extracellular vesicles, encapsulated cell technology and biomaterial scaffolds. We synthesize clinical evidence across age-related macular degeneration, inherited retinal dystrophies, and corneal injury/limbal stem-cell deficiency, and highlight emerging applications for glaucoma and diabetic retinopathy. Delivery routes (subretinal, intravitreal, anterior segment) and graft formats (single cells, sheets/patches, organoids) are compared using standardized structural and functional endpoints. Persistent barriers include GMP-compliant derivation and release testing; differentiation fidelity, maturation, and potency; genomic stability and tumorigenicity risk; graft survival, synaptic integration, and immune rejection despite ocular immune privilege; the scarcity of validated biomarkers and harmonized outcome measures and ethical, regulatory, and health-economic constraints. Promising trajectories span off-the-shelf allogeneic products, patient-specific iPSC-derived grafts, organoid and 3D-bioprinted tissues, gene-plus-cell combinations, and cell-free extracellular-vesicle therapeutics. Overall, cell-based therapies remain investigational. With adequately powered trials, methodological harmonization, long-term surveillance, scalable xeno-free manufacturing, and equitable access frameworks, they may eventually become standards of care; at present, approvals are limited to specific products/indications and regions, and no cell therapy is the standard of care for retinal disease. Full article
(This article belongs to the Special Issue Advances in Biomedical Frontier Technologies and Disease Diagnosis)
Show Figures

Figure 1

Back to TopTop